Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 22, 2018
- Accepted in final form September 19, 2018
- First Published January 9, 2019.
Article Versions
- Previous version (January 9, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Ruben P.A. van Eijk, MD, MSc,
- Henk-Jan Westeneng, MD,
- Stavros Nikolakopoulos, PhD,
- Iris E. Verhagen, MD,
- Michael A. van Es, MD, PhD,
- Marinus J.C. Eijkemans, PhD and
- Leonard H. van den Berg, MD, PhD
- Ruben P.A. van Eijk, MD, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Henk-Jan Westeneng, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stavros Nikolakopoulos, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Iris E. Verhagen, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael A. van Es, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marinus J.C. Eijkemans, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Leonard H. van den Berg, MD, PhD
Scientific Advisory Boards of Biogen, Cytokinetics, Wave Life Sciences, Freeway, Sarepta
NONE
Octapharma, Shire
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal of Neurology, Neurosurgery and Psychiatry Neuromuscular Disorders
NONE
NONE
NONE
NONE
NONE
received an educational grant from Shire
NONE
NONE
NONE
NONE
The Netherlands ALS Foundation; Netherlands Organisation for Health Research and Development (Vici scheme)
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (R.P.A.v.E., H.-J.W., I.E.V., M.A.v.E., L.H.v.d.B.), Brain Center Rudolf Magnus, and Biostatistics & Research Support (R.P.A.v.E., S.N., M.J.C.E.), Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands.
- Correspondence
Dr. van den Berg lberg{at}umcutrecht.nl
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.